Mar­ket crash slumps biotech as in­vestors yank $1.2B from funds

Af­ter soar­ing 11% on the highs of JPM hype and mega-sized merg­ers and ac­qui­si­tions, the Nas­daq Biotech In­dex is tum­bling in Feb­ru­ary.

That rapid down­shift …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA